Image source: © Sofiaworld | Megapixl.com
Highlights
- Mesoblast is an ASX-listed biotech firm focused on developing allogenic cellular medicines for treating severe and life-threatening inflammatory conditions
- In FY23, MSB’s revenue from royalties dropped by 26.5% YoY and commercialization revenue fell by 17% YoY
- Itescu (Silviu) has maximum stake in MSB with a shareholding of nearly 7.78%
Mesoblast Limited (ASX: MSB) is a biotech company which is focused on developing allogenic cellular medicines for treating severe and life-threatening inflammatory conditions. The company manages a portfolio of late-stage product candidate.
In the financial year 2023 (FY23), the company recorded 26.5% YoY decline in revenue from royalties to USD 7.5 million and 17% YoY decline in commercialization revenue to USD 7.5 million. The decline in revenue was driven by a singular achievement from Takeda related to the approval of Alofisel in Japan in FY22.
The company is committed on gaining the US FDA approval for its lead mesenchymal stromal cell product Ryoncil.
Top 10 shareholders of MSB
The top 10 shareholders of MSB have nearly 23.85% shareholding in the company, while top four have 16.68% shareholdings. The highest stakes are held by Itescu (Silviu) and G to the Fourth Investments LLC, with a shareholding of nearly 7.78% and 3.87%, respectively.
Recent business update
On 31 January 2024, the company shared recent quarter results. During the quarter, the company reported progress across its three lead Phase 3 assets.
The period saw a capital raise of AUD 60.3 million and at the end of quarter, cash balance was USD 77.6 million. Revenue from royalties on sale of TEMCELL HS Inj.5 sold in Japan by the MSB’s licensee stood at USD 1.5 million.
Outlook
The focus is on advancing the Phase 3 programs in adults with SR-aGVHD and in chronic inflammatory low back pain. Moreover, cost reduction strategies are being conducted to preserve cash and strengthen balance sheet.
The company intends to tap international scale partnerships to fund clinical campaigns.
Share performance of MSB
MSB shares closed 1.79% down at AUD 0.275 apiece on 14 February 2024. With this, MSB’s share price has declined by 71.28% in the last one year and has recorded a fall of 26.57% in the past six months.
The 52-week high of MSB is AUD 1.35, recorded on 17 July 2023, while the 52-week low is AUD 0.255, recorded on 8 February 2024.

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, and currency, is 14 February 2024. The reference data in this report has been partly sourced from REFINITIV.
Disclaimer:
This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.
Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.
Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.
The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.
The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.
Kalkine does not issue, sell or deal in any financial products.
This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.
To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.
Copyright 2026 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this Article, or its content, may be reproduced in any form without our prior consent.